Abstract

Bladder cancer (BCA) is one of the most common cancers. In 2010 in Poland, 6296 people developed bladder cancer and 3110 people died of it. Immunotherapy with BCG (Bacillus Calmette-Guérin) is by far the most effective adjuvant therapy. Noninfiltrating muscle membrane changes, that is, stages Ta, Tis and T1 qualify for BCG immunotherapy. BCG immunotherapy comprises series of bladder instillations, containing attenuated strain of Mycobacterium bovis. The effectiveness of immunotherapy in non-invasive bladder cancer is 70% 5-year survival without recurrence of the tumor. The treatment leads to a reduction of the residual tumor mass, but also to the delay and/or prevention of relapse, disease progression and ultimately death. Cytokines, as key mediators of immune response, play an important role in the pathogenesis of bladder cancer, which occurrence is stimulated by the inflammatory process. BCG immunotherapy provokes an intensive immunological response by the increase of cytokine production. Genetic variants determine inter-individual differences in the incidence of this cancer, as well as the response to the therapy. This is evidenced by the presence of differences in genetic variants of cytokines correlated with the varied risk of bladder cancer incidence. It is believed that concentrations of particular cytokines in urine after installation of BCG may indicate response to the therapy. Increased levels of Th1 cytokines – IFN-γ, IL-2 and TNF-α are correlated with longer survival time without recurrence, whereas high levels of Th2 cytokines such as IL-10, predict unsuccessful BCG therapy.

References

• 1. Agarwal A., Agrawal U., Verma S., Mohanty N.K., Saxena S.: SerumTh1 and Th2 cytokine balance in patients of superficial transitionalcell carcinoma of bladder pre- and post-intravesical combination immunotherapy.Immunopharmacol. Immunotoxicol., 2010; 32: 348-356
  Google Scholar
• 2. Agarwal A., Verma S., Burra U., Murthy N.S., Mohanty N.K., SaxenaS.: Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs asa parameter of immunological dysfunction in patients of superficialtransitional cell carcinoma of bladder. Cancer Immunol. Immunother.,2006; 55: 734-743
  Google Scholar
• 3. Ahirwar D.K., Agrahari A., Mandhani A., Mittal R.D.: Cytokine genepolymorphisms are associated with risk of urinary bladder cancer andrecurrence after BCG immunotherapy. Biomarkers, 2009; 14: 213-218
  Google Scholar
• 4. Ahirwar D., Kesarwani P., Manchanda P.K., Mandhani A., MittalR.D.: Anti- and proinflammatory cytokine gene polymorphismand genetic predisposition: association with smoking, tumor stageand grade, and bacillus Calmette-Guérin immunotherapy inbladder cancer. Cancer Genet. Cytogenet., 2008; 184: 1-8
  Google Scholar
• 5. Ahirwar D.K., Manchanda P.K., Mittal R.D., Bid H.K.: BCG responseprediction with cytokine gene variants and bladder cancer: wherewe are? J. Cancer Res. Clin. Oncol., 2011; 137: 1729-1738
  Google Scholar
• 6. Ahirwar D.K., Mandhani A., Dharaskar A., Kesarwani P., Mittal R.D.: Associationof tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T)polymorphisms with bladder cancer susceptibility and outcome afterbacille Calmette-Guérin immunotherapy. BJU Int., 2009; 104: 867-873
  Google Scholar
• 7. Ahirwar D.K., Mandhani A., Mittal R.D.: IL-8 -251 T > A polymorphismis associated with bladder cancer susceptibility and outcomeafter BCG immunotherapy in a northern Indian cohort. Arch. Med.Res., 2010; 41: 97-103
  Google Scholar
• 8. Arend W.P., Malyak M., Guthridge C.J., Gabay C.: Interleukin-1receptor antagonist: role in biology. Annu. Rev. Immunol., 1998;16: 27-55
  Google Scholar
• 9. Ayari C., LaRue H., Hovington H., Decobert M., Harel F., BergeronA., Tetu B., Lacombe L., Fradet Y.: Bladder tumor infiltrating maturedendritic cells and macrophages as predictors of response to bacillusCalmette-Guérin immunotherapy. Eur. Urol., 2009; 55: 1386-1395
  Google Scholar
• 10. Babjuk M., Burger M.: Guidelines on non-muscle invasive bladdercancer. European Association of Urology, 2013 edition.
  Google Scholar
• 11. Balkwill F., Charles K.A., Mantovani A.: Smoldering and polarizedinflammation in the initiation and promotion of malignant disease.Cancer Cell, 2005; 7: 211-217
  Google Scholar
• 12. Banu N., Mozes M.M., Kopp J.B., Ziyadeh F.N., Meyers C.M.: Regulationof inducible class II MHC, costimulatory molecules, andcytokine expression in TGF-β1 knockout renal epithelial cells: effectof exogenous TGF-β1. Exp. Nephrol., 2002; 10: 320-331
  Google Scholar
• 13. Basturk B., Yavascaoglu I., Oral B., Göral G., Oktay B.: Cytokinegene polymorphisms can alter the effect of Bacillus Calmette-Guérin(BCG) immunotherapy. Cytokine, 2006; 35: 1-5
  Google Scholar
• 14. Bekker L.G., Freeman S., Murray P.J., Ryffel B., Kaplan G.: TNF-αcontrols intracellular mycobacterial growth by both inducible nitricoxide synthase-dependent and inducible nitric oxide synthase-independentpathways. J. Immunol., 2001; 166: 6728-6734
  Google Scholar
• 15. Bid H.K., Manchanda P.K., Mittal R.D.: Association of interleukin-1Ragene polymorphism in patients with bladder cancer: casecontrol study from North India. Urology, 2006; 67: 1099-1104
  Google Scholar
• 16. Biet F., Kremer L., Wolowczuk I., Delacre M., Locht C.: Immuneresponse induced by recombinant Mycobacterium bovis BCG producingthe cholera toxin B subunit. Infect. Immun., 2003; 71: 2933-2937
  Google Scholar
• 17. Böhle A., Thanhäuser A., Ulmer A.J., Ernst M., Flad H.D., JochamD.: Dissecting the immunobiological effects of Bacillus Calmette-Gu-érin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK)cell phenomenon. J. Urol., 1993; 150: 1932-1937
  Google Scholar
• 18. Böhle A., Thanhäuser A., Ulmer A.J., Mattern T., Ernst M., FladH.D., Jocham D.: On the mode of action of intravesical bacillus Calmette-Guerin:in vitro characterization of BCG-activated killer cells.Urol. Res., 1994; 22: 185-190
  Google Scholar
• 19. Brandau S., Böhle A.: Activation of natural killer cells by BacillusCalmette-Guérin. Eur. Urol., 2001; 39: 518-524
  Google Scholar
• 20. Burke F., Relf M., Negus R., Balkwill F.: A cytokine profile of normaland malignant ovary. Cytokine, 1996; 8: 578-585
  Google Scholar
• 21. Campbell-Walsh Urology, 10th Edition, Philadelphia, Elsevier,2012
  Google Scholar
• 22. Cormio L., Tolve I., Annese P., Saracino A., Zamparese R., SanguedolceF., Bufo P., Battaglia M., Selvaggi F.P., Carrieri G.: Altered p53and pRb expression is predictive of response to BCG treatment inT1G3 bladder cancer. Anticancer Res., 2009; 29: 4201-4204
  Google Scholar
• 23. Coussens L.M., Werb Z.: Inflammation and cancer. Nature, 2002;420: 860-867
  Google Scholar
• 24. Das S.K., Hashimoto T., Shimizu K., Yoshida T., Sakai T., Sowa Y.,Komoto A., Kanazawa K.: Fucoxanthin induces cell cycle arrest atG0/G1 phase in human colon carcinoma cells through up-regulationof p21WAF1/Cip1. Biochim. Biophys. Acta, 2005; 1726: 328-335
  Google Scholar
• 25. De Boer E.C., De Jong W.H., Van der Meijden A.P., SteerenbergP.A., Witjes J.A., Vegt P.D., Debruyne F.M., Ruitenberg E.J.: Presenceof activated lymphocytes in the urine of patients with superficialbladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.Cancer Immunol. Immunother., 1991; 33: 411-416
  Google Scholar
• 26. De Boer E.C., Rooijakkers S.J., Schamhart D.H., Kurth K.H.: Cytokinegene expression in a mouse model: the first instillations withviable bacillus Calmette-Guerin determine the succeeding Th1 response.J. Urol., 2003; 170: 2004-2008
  Google Scholar
• 27. de Reijke T.M., de Boer E.C., Kurth K.H., Schamhart D.H.: Urinarycytokines during intravesical bacillus Calmette-Guerin therapyfor superficial bladder cancer: processing, stability and prognosticvalue. J. Urol., 1996; 155: 477-482
  Google Scholar
• 28. De Wever O., Mareel M.: Role of tissue stroma in cancer cell invasion.J. Pathol., 2003; 200: 429-447
  Google Scholar
• 29. Decobert M., Larue H., Bergeron A., Harel F., Pfister C., RousseauF., Lacombe L., Fradet Y.: Polymorphisms of the human NRAMP1 geneare associated with response to bacillus Calmette-Guerin immunotherapyfor superficial bladder cancer. J. Urol., 2006; 175: 1506-1511
  Google Scholar
• 30. Durek C., Richter E., Basteck A., Rüsch-Gerdes S., Gerdes J., JochamD., Böhle A.: The fate of bacillus Calmette-Guerin after intravesicalinstillation. J. Urol., 2001; 165: 1765-1768
  Google Scholar
• 31. Eble J., Sauter G., Epstein J., Sesterhenn I.: Patology and Geneticsof Tumor of the Urinary System and Male Genital Organs, IARCPress, Lyon, 2004
  Google Scholar
• 32. Ehdaie B., Sylvester R., Herr H.W.: Maintenance bacillus Calmette-Guérintreatment of non-muscle-invasive bladder cancer:a critical evaluation of the evidence. Eur. Urol., 2013; 64: 579-585
  Google Scholar
• 33. Esuvaranathan K., Chiong E., Thamboo T.P., Chan Y.H., KamarajR., Mahendran R., Teh M.: Predictive value of p53 and pRb expressionin superficial bladder cancer patients treated with BCG andinterferon-alpha. Cancer, 2007; 109: 1097-1105
  Google Scholar
• 34. Ganesan P.L., Alexander S.I., Watson D., Logan G.J., Zhang G.Y.,Alexander I.E.: Robust anti-tumor immunity and memory in Rag–1-deficient mice following adoptive transfer of cytokine-primedsplenocytes and tumor CD80 expression. Cancer Immunol. Immunother.,2007; 56: 1955-1965
  Google Scholar
• 35. Goggins M., Shekher M., Turnacioglu K., Yeo C.J., Hruban R.H.,Kern S.E.: Genetic alterations of the transforming growth factor βreceptor genes in pancreatic and biliary adenocarcinomas. CancerRes., 1998; 58: 5329-5332
  Google Scholar
• 36. Grau L., Luque-Garcia J.L., González-Peramato P., TheodorescuD., Palou J., Fernandez-Gomez J.M., Sánchez-Carbayo M.: A quantitativeproteomic analysis uncovers the relevance of CUL3 in bladdercancer aggressiveness. PLoS One, 2013; 8: e53328
  Google Scholar
• 37. Groah S.L., Weitzenkamp D.A., Lammertse D.P., Whiteneck G.G.,Lezotte D.C., Hamman R.F.: Excess risk of bladder cancer in spinalcord injury: evidence for an association between indwelling catheteruse and bladder cancer. Arch. Phys. Med. Rehabil., 2002; 83: 346-351
  Google Scholar
• 38. Hussain S.P., Hofseth L.J., Harris C.C.: Radical causes of cancer.Nat. Rev. Cancer, 2003; 3: 276-285
  Google Scholar
• 39. Kaempfer R., Gerez L., Farbstein H., Madar L., Hirschman O.,Nussinovich R., Shapiro A.: Prediction of response to treatment insuperficial bladder carcinoma through pattern of interleukin-2 geneexpression. J. Clin. Oncol., 1996; 14: 1778-1786
  Google Scholar
• 40. Kavoussi L.R., Brown E.J., Ritchey J.K., Ratliff T.L.: Fibronectin–mediated Calmette-Guerin bacillus attachment to murine bladdermucosa. Requirement for the expression of an antitumor response.J. Clin. Invest., 1990; 85: 62-67
  Google Scholar
• 41. Kim Y.J., Ha Y.S., Kim S.K., Yoon H.Y., Lym M.S., Kim M.J., MoonS.K., Choi Y.H., Kim W.J.: Gene signatures for the prediction of responseto bacillus Calmette-Guerin immunotherapy in primary pT1bladder cancers. Clin. Cancer Res., 2010; 16: 2131-2137
  Google Scholar
• 42. Kitamura H., Tsukamoto T.: Immunotherapy for urothelial carcinoma:current status and perspectives. Cancers, 2011; 3: 3055-3072
  Google Scholar
• 43. Kołodziej A.: Immunoterapia BCG raków pęcherza moczowegoz uwzględnieniem własnego systemu czynników rokowniczych – Rozprawa na stopień doktora habilitowanego, Uniwersytet Medycznywe Wrocławiu, 2007
  Google Scholar
• 44. Kolodziej A., Dembowski J., Zdrojowy R., Wozniak P., Lorenz J.:Treatment of high-risk superficial bladder cancer with maintenancebacille Calmette-Guérin therapy: preliminary results. BJU Int.,2002; 89: 620-622
  Google Scholar
• 45. Konwar R., Chaudhary P., Kumar S., Mishra D., ChattopadhyayN., Bid H.K.: Breast cancer risk associated with polymorphisms ofIL-1RN and IL-4 gene in Indian women. Oncol. Res., 2009; 17: 367-372
  Google Scholar
• 46. Krajowa Baza Danych Nowotworowych, Centrum Onkologii –instytut w Warszawie. http://85.128.14.124/krn (19.10.2013)
  Google Scholar
• 47. Kumar A., Dubey D., Bansal P., Mandhani A., Naik S.: Urinaryinterleukin-8 predicts the response of standard and low dose intravesicalbacillus Calmette-Guerin (modified Danish 1331 strain) forsuperficial bladder cancer. J. Urol., 2002; 168: 2232-2235
  Google Scholar
• 48. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., GottesmanJ.E., Lowe B.A., Sarosdy M.F., Bohl R.D., Grossman H.B., BeckT.M., Leimert J.T., Crawford ED.: Maintenance bacillus Calmette–Guerin immunotherapy for recurrent TA, T1 and carcinoma in situtransitional cell carcinoma of the bladder: a randomized SouthwestOncology Group Study. J. Urol., 2000; 163: 1124-1129
  Google Scholar
• 49. Lamm D.L., Blumenstein B.A., David Crawford E., Crissman J.D.,Lowe B.A., Smith J.A. Jr., Sarosdy M.F., Schellhammer P.F., SagalowskyA.I., Messing E.M., Loehrer P., Barton Grossman H.: Randomizedintergroup comparison of bacillus Calmette-Guerin immunotherapyand mitomycin C chemotherapy prophylaxis in superficial transitionalcell carcinoma of the bladder a southwest oncology group study.Urol. Oncol., 1995; 1: 119-126
  Google Scholar
• 50. Lamm D.L., Blumenstein J.D., Sarosdy M.J., Brent A.L., CrawfordE.D.: Significant long-term patient benefit with BCG maintenancetherapy. J. Urol., 1997; 157; 831-832
  Google Scholar
• 51. Leibovici D., Grossman H.B., Dinney C.P., Millikan R.E., LernerS., Wang Y., Gu J., Dong Q., Wu X.: Polymorphisms in inflammationgenes and bladder cancer: from initiation to recurrence, progression,and survival. J. Clin. Oncol., 2005; 23: 5746-5756
  Google Scholar
• 52. Lin W.W., Karin M.: A cytokine-mediated link between innateimmunity, inflammation, and cancer. J. Clin. Invest., 2007; 117:1175-1183
  Google Scholar
• 53. Ludwig A.T., Moore J.M., Luo Y., Chen X., Saltsgaver N.A., O’DonnellM.A., Griffith T.S.: Tumor necrosis factor-related apoptosis-inducingligand: a novel mechanism for bacillus Calmette-Guérin-inducedantitumor activity. Cancer Res., 2004; 64: 3386-3390
  Google Scholar
• 54. Luo Y., Chen X., Downs T.M., DeWolf W.C., O’Donnell M.A.: IFN-α2B enhances Th1 cytokine responses in bladder cancer patients receivingMycobacterium bovis bacillus Calmette-Guérin immunotherapy.J. Immunol., 1999; 162: 2399-2405
  Google Scholar
• 55. Mehmut M., Takeda K., Abe M., Ogata H., Hirose S., Okumura K.,Fujime M.: Fas ligand and TNF-related apoptosis-inducing ligand inductionon infiltrating lymphocytes in bladder carcinoma by bacillusCalmette-Guérin treatment. Urol. Int., 2005; 75: 80-87
  Google Scholar
• 56. Michaud D.S.: Chronic inflammation and bladder cancer. Urol.Oncol., 2007; 25: 260-268
  Google Scholar
• 57. Mittal R.D., Manchanda P.K., Bid H.K., Ghoshal U.C.: Analysis ofpolymorphisms of tumor necrosis factor-α and polymorphic xenobioticmetabolizing enzymes in inflammatory bowel disease: studyfrom northern India. J. Gastroenterol. Hepatol., 2007; 22: 920-924
  Google Scholar
• 58. Montironi R., Lopez-Beltran A.: The 2004 WHO classification ofbladder tumors: a summary and commentary. Int. J. Surg. Pathol.,2005; 13: 143-153
  Google Scholar
• 59. Moore K.W., de Waal Malefyt R., Coffman R.L., O’Garra A.: Interleukin-10and interleukin-10 receptor. Annu. Rev. Immunol., 2001;19: 683-765
  Google Scholar
• 60. Morales A., Eidinger D., Bruce A.W.: Intracavitary Bacillus Calmette-Guerinin the treatment of superficial bladder tumors. J. Urol.,2002; 167: 891-893
  Google Scholar
• 61. Nadler R., Luo Y., Zhao W., Ritchey J.K., Austin J.C., Cohen M.B.,O’Donnel M.A., Ratliff T.L.: Interleukin 10 induced augmentation ofdelayed-type hypersensitivity (DTH) enhances Mycobacterium bovisbacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin.Exp. Immunol., 2003; 131: 206-216
  Google Scholar
• 62. Palou J., Algaba F., Vera I., Rodriguez O., Villavicencio H., Sanchez-CarbayoM.: Protein expression patterns of ezrin are predictorsof progression in T1G3 bladder tumours treated with nonmaintenancebacillus Calmette-Guérin. Eur. Urol., 2009; 56: 829-836
  Google Scholar
• 63. Pawinski A., Sylvester R., Kurth K.H., Bouffioux C., van der MeijdenA., Parmar M.K., Bijnens L.: A combined analysis of Europeanorganization for research and treatment of cancer, and medical researchcouncil randomized clinical trails for the prophylactic treatmentof stage TaT1 bladder cancer. J. Urol., 1996; 156: 1934-1940
  Google Scholar
• 64. Pooja S., Francis A., Bid H.K., Kumar S., Rajender S., RamalingamK., Thangaraj K., Konwar R.: Role of ethnic variations in TNF-αand TNF-β polymorphisms and risk of breast cancer in India. BreastCancer Res Treat, 2011; 126: 739-747
  Google Scholar
• 65. Przybylski G., Wielikdzień J., Kopiński P.: Mechanisms of programmedcell death of effector T lymphocytes. Postępy Hig. Med.Dośw., 2013; 67: 1374-1390
  Google Scholar
• 66. Rabinowitz R., Smith D.S., Tiemann D.D., Hudson M.A.: Urinaryinterleukin-8/creatinine level as a predictor of response to intravesicalbacillus Calmette-Guerin therapy in bladder tumor patients. J.Urol., 1997; 158: 1728-1731
  Google Scholar
• 67. Reznikoff C.A., Sarkar S., Jülicher K.P., Burger M.S., PuthenveettilJ.A., Jarrard D.F., Newton M.A.: Genetic alterations and biologicalpathways in human bladder cancer pathogenesis. Urol. Oncol.,2000; 5: 191-203
  Google Scholar
• 68. Sagnak L., Ersoy H., Ozok U., Senturk B., Ercil H., Bahar G., OzturkE.: Predictive value of urinary interleukin-8 cutoff point for recurrencesafter transurethral resection plus induction bacillus Calmette-Guerintreatment in non-muscle-invasive bladder tumors. Clin.Genitourin. Cancer, 2009; 7: E16-E23
  Google Scholar
• 69. Saint F., Kurth N., Maille P., Vordos D., Hoznek A., Soyeux P., PatardJ.J., Abbou C.C., Chopin D.K.: Urinary IL-2 assay for monitoringintravesical bacillus Calmette-Guérin response of superficial bladdercancer during induction course and maintenance therapy. Int.J. Cancer, 2003; 107: 434-440
  Google Scholar
• 70. Saint F., Patard J.J., Groux Muscatelli B., Lefrere Belda M.A.,Gil Diez de Medina S., Abbou C.C., Chopin D.K.: Evaluation of cellulartumour rejection mechanisms in the peritumoral bladderwall after bacillus Calmette-Guérin treatment. BJU Int., 2001;88: 602-610
  Google Scholar
• 71. Saint F., Patard J.J., Irani J., Salomon L., Hoznek A., Legrand P.,Debois H., Abbou C.C., Chopin D.K.: Leukocyturia as a predictor oftolerance and efficacy of intravesical BCG maintenance therapy forsuperficial bladder cancer. Urology, 2001; 57: 617-621
  Google Scholar
• 72. Saint F., Salomon L., Quintela R., Cicco A., Hoznek A., Abbou C.C.,Chopin D.K.: Do prognostic parameters of remission versus relapseafter Bacillus Calmette-Guérin (BCG) immunotherapy exist?: analysisof a quarter century of literature. Eur. Urol., 2003; 43: 351-360
  Google Scholar
• 73. Schmiegel W., Roeder C., Schmielau J., Rodeck U., Kalthoff H.:Tumor necrosis factor α induces the expression of transforminggrowth factor α and the epidermal growth factor receptor in humanpancreatic cancer cells. Proc. Natl. Acad. Sci. USA, 1993; 90: 863-867
  Google Scholar
• 74. Sethi G., Sung B., Aggarwal B.: TNF: a master switch for inflammationto cancer. Front Biosci., 2008; 13: 5094-5107
  Google Scholar
• 75. Shintani Y., Sawada Y., Inagaki T., Kohjimoto Y., Uekado Y., ShinkaT.: Intravesical instillation therapy with Bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of BacillusCalmette-Guérin immunotherapy. Int. J. Urol., 2007; 14: 140-146
  Google Scholar
• 76. Simons M.P., O’Donnell M.A., Griffith T.S.: Role of neutrophilsin BCG immunotherapy for bladder cancer. Urol. Oncol., 2008; 26:341-345
  Google Scholar
• 77. Stricker P., Pryor K., Nicholson T., Goldstein D., Golovsky D.,Ferguson R., Nash P., Ehsman S., Rumma J., Mammen G., Penny R.:Bacillus Calmette-Guérin plus intravesical interferon alpha-2b inpatients with superficial bladder cancer. Urology, 1996; 48: 957-961
  Google Scholar
• 78. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., FujikiH.: Essential role of tumor necrosis factor α (TNF-α) in tumorpromotion as revealed by TNF-α-deficient mice. Cancer Res., 1999;59: 4516-4518
  Google Scholar
• 79. Talar B., Czyż M.: TGF-β signaling pathways in cancers. PostępyHig. Med. Dośw., 2013; 67: 1008-1017
  Google Scholar
• 80. Thalmann G.N., Dewald B., Baggiolini M., Studer U.E.: Interleukin-8expression in the urine after bacillus Calmette-Guerin therapy:a potential prognostic factor of tumor recurrence and progression.J. Urol., 1997; 158: 1340-1344
  Google Scholar
• 81. Thalmann G.N., Sermier A., Rentsch C., Möhrle K., CecchiniM.G., Studer U.E.: Urinary interleukin-8 and 18 predict the responseof superficial bladder cancer to intravesical therapy with bacillusCalmette-Guerin. J. Urol., 2000; 164: 2129-2133
  Google Scholar
• 82. van der Meijden A.P., Sylvester R.J., Oosterlinck W., Hoeltl W.,Bono A.V.; EORTC Genito-Urinary Tract Cancer Group: MaintenanceBacillus Calmette-Guerin for Ta T1 bladder tumors is not associatedwith increased toxicity: results from a European Organisation forResearch and Treatment of Cancer Genito-Urinary Group Phase IIITrial. Eur. Urol., 2003; 44: 429-434
  Google Scholar
• 83. Watanabe E., Matsuyama H., Matsuda K.: Urinary interleukin-2may predict clinical outcome of intravesical bacillus Calmette-Gu-érin immunotherapy for carcinoma in situ of the bladder. CancerImmunol. Immunother., 2003; 52: 481-486
  Google Scholar
• 84. Xu W., Liu L.Z., Loizidou M., Ahmed M., Charles I.G.: The role ofnitric oxide in cancer. Cell Res., 2002; 12: 311-320
  Google Scholar
• 85. Yamaguchi Y., Tsumura H., Miwa M., Inaba K.: Contrasting effectsof TGF-β1 and TNFα on the development of dendritic cells fromprogenitors in mouse bone marrow. Stem Cells, 1997; 15: 144-153
  Google Scholar
• 86. Zaharoff D.A., Hoffman B.S., Hooper H.B., Benjamin C.J.Jr., KhuranaK.K., Hance K.W., Rogers C.J., Pinto P.A., Schlom J., Greiner J.W.:Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.Cancer Res., 2009; 69: 6192-6199
  Google Scholar
• 87. Zlotta A.R., Noel J.C., Fayt I., Drowart A., Van Vooren J.P., HuygenK., Simon J., Schulman C.C.: Correlation and prognostic significanceof p53, p21WAF1/CIP1 and Ki-67 expression in patients withsuperficial bladder tumors treated with bacillus Calmette-Guerinintravesical therapy. J. Urol., 1999; 161: 792-798
  Google Scholar
• 88. Zuiverloon T.C., Nieuweboer A.J., Vékony H., Kirkels W.J., BangmaC.H., Zwarthoff E.C.: Markers predicting response to bacillus Calmette-Guérinimmunotherapy in high-risk bladder cancer patients:a systematic review. Eur. Urol., 2012; 61: 128-145
  Google Scholar

Full text